  The lncRNA HOTAIR has been implicated in several human cancers. Here, we
evaluated the molecular alterations and upstream regulatory mechanisms of
HOTAIR in glioma, the most common primary brain tumors, and its clinical
relevance. HOTAIR gene expression, methylation, copy-number and prognostic
value were investigated in human gliomas integrating data from online datasets
and our cohorts. High levels of HOTAIR were associated with higher grades of
glioma, particularly IDH wild-type cases. Mechanistically, HOTAIR was
overexpressed in a gene dosage-independent manner, while DNA methylation levels
of particular CpGs in HOTAIR locus were associated with HOTAIR expression
levels in GBM clinical specimens and cell lines. Concordantly, the
demethylating agent 5-Aza-2'-deoxycytidine affected HOTAIR transcriptional
levels in a cell line-dependent manner. Importantly, HOTAIR was frequently
co-expressed with HOXA9 in high-grade gliomas from TCGA, Oncomine, and our
Portuguese and French datasets. Integrated in silico analyses, chromatin
immunoprecipitation, and qPCR data showed that HOXA9 binds directly to the
promoter of HOTAIR. Clinically, GBM patients with high HOTAIR expression had a
significantly reduced overall survival, independently of other prognostic
variables. In summary, this work reveals HOXA9 as a novel direct regulator of
HOTAIR, and establishes HOTAIR as an independent prognostic marker, providing
new therapeutic opportunities to treat this highly aggressive cancer.
